These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36949264)

  • 41. Regulation of Diabetes: a Therapeutic Strategy for Alzheimer's Disease?
    Ahn KC; Learman CR; Baker GB; Weaver CL; Chung PS; Kim HG; Song MS
    J Korean Med Sci; 2019 Dec; 34(46):e297. PubMed ID: 31779058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alzheimer's disease and diabetes: new insights and unifying therapies.
    Vignini A; Giulietti A; Nanetti L; Raffaelli F; Giusti L; Mazzanti L; Provinciali L
    Curr Diabetes Rev; 2013 May; 9(3):218-27. PubMed ID: 23363296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk: A Mendelian Randomization Study.
    Tang B; Wang Y; Jiang X; Thambisetty M; Ferrucci L; Johnell K; Hägg S
    Neurology; 2022 Aug; 99(7):e650-e659. PubMed ID: 35654594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inflammatory hypothesis as a link between Alzheimer's disease and diabetes mellitus.
    Bozluolcay M; Andican G; Fırtına S; Erkol G; Konukoglu D
    Geriatr Gerontol Int; 2016 Oct; 16(10):1161-1166. PubMed ID: 26337250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alzheimer's disease and type 2 diabetes: what is the connection?
    Greene A; Ng J; Shepherd L; Carey K
    Consult Pharm; 2015 Feb; 30(2):112-5. PubMed ID: 25695417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of antidiabetic agents on Alzheimer's disease biomarkers in experimentally induced hyperglycemic rat model by streptozocin.
    Ali SK; Ali RH
    PLoS One; 2022; 17(7):e0271138. PubMed ID: 35802659
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin.
    Lin HC; Chung CH; Chen LC; Wang JY; Chen CC; Huang KY; Tsai MH; Chien WC; Lin HA
    Sci Rep; 2023 Apr; 13(1):6625. PubMed ID: 37095270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of Microtubule Affinity Regulating Kinase 4 by Metformin: Exploring the Neuroprotective Potential of Antidiabetic Drug through Spectroscopic and Computational Approaches.
    Ashraf GM; DasGupta D; Alam MZ; Baeesa SS; Alghamdi BS; Anwar F; Alqurashi TMA; Sharaf SE; Al Abdulmonem W; Alyousef MA; Alhumaydhi FA; Shamsi A
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer's Disease-Diabetes Dual Therapy.
    Rizvi SM; Shaikh S; Naaz D; Shakil S; Ahmad A; Haneef M; Abuzenadah AM
    Neurochem Res; 2016 Jun; 41(6):1475-82. PubMed ID: 26886763
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of metformin use with Alzheimer's disease in patients with newly diagnosed type 2 diabetes: a population-based nested case-control study.
    Ha J; Choi DW; Kim KJ; Cho SY; Kim H; Kim KY; Koh Y; Nam CM; Kim E
    Sci Rep; 2021 Dec; 11(1):24069. PubMed ID: 34912022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4.
    Chen S; Liu AR; An FM; Yao WB; Gao XD
    Age (Dordr); 2012 Oct; 34(5):1211-24. PubMed ID: 21901364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alzheimer's disease and insulin resistance: translating basic science into clinical applications.
    De Felice FG
    J Clin Invest; 2013 Feb; 123(2):531-9. PubMed ID: 23485579
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fighting Alzheimer's disease and type 2 diabetes: pathological links and treatment strategies.
    Dai Y; Kamal MA
    CNS Neurol Disord Drug Targets; 2014 Mar; 13(2):271-82. PubMed ID: 24059324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.
    Watson GS; Craft S
    CNS Drugs; 2003; 17(1):27-45. PubMed ID: 12467491
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Type 3 diabetes (Alzheimer's disease): new insight for promising therapeutic avenues.
    Candasamy M; Mohamed Elhassan SA; Kumar Bhattamisra S; Hua WY; Sern LM; Binti Busthamin NA; Mohamad Ilni NB; Shun NS; Baohong L; Ya NS; Ying NW
    Panminerva Med; 2020 Sep; 62(3):155-163. PubMed ID: 32208408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ameliorating effect of anti-Alzheimer's drugs on the bidirectional association between type 2 diabetes mellitus and Alzheimer's disease.
    Ahmed AS; Elgharabawy RM; Al-Najjar AH
    Exp Biol Med (Maywood); 2017 Jul; 242(13):1335-1344. PubMed ID: 28534431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alterations in Glucose Metabolism in Alzheimer's Disease.
    Calsolaro V; Edison P
    Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):31-39. PubMed ID: 27306508
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Past and current perspective on new therapeutic targets for Type-II diabetes.
    Patil PD; Mahajan UB; Patil KR; Chaudhari S; Patil CR; Agrawal YO; Ojha S; Goyal SN
    Drug Des Devel Ther; 2017; 11():1567-1583. PubMed ID: 28579755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer's Disease and Depression.
    El Massry M; Alaeddine LM; Ali L; Saad C; Eid AA
    Curr Med Chem; 2021; 28(12):2328-2345. PubMed ID: 32900343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.
    Avgerinos KI; Kalaitzidis G; Malli A; Kalaitzoglou D; Myserlis PG; Lioutas VA
    J Neurol; 2018 Jul; 265(7):1497-1510. PubMed ID: 29392460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.